Bristol-Myers, Celgene link up for immuno-oncology combo trials
This article was originally published in Scrip
Celgene has been bolstering Abraxane sales through added indications and now the big biotech is hoping to see a surge in the chemotherapy drug's revenues when it is paired with Bristol-Myers Squibb's highly anticipated immuno-oncology product nivolumab.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.